Kelly Holman

KELLY HOLMAN is a Founder and Managing Director of Genesys Capital and
has extensive commercial and technical experience in the biotechnology
industry. Since co-founding Genesys Capital Partners in 2000, he has
been actively involved in assisting the Triax-Covington NewGen Funds
raise over $100 million of venture capital and has been instrumental in
deploying over $60 million across 16 investments. He serves on the Board
of Directors of Affinium Pharmaceuticals Inc., Epocal Inc., matRegen
Corp. and Interface Biologics Inc. He is active in deal origination and
company creation and has advised Canada’s National Biotechnology
Advisory Committee on strategies for financing startup and early-stage
biotechnology companies. He holds a Bachelor of Science (honors) in
Biochemistry and an MBA, both from Queen’s University.